Let's not forget that Tony was not a CEO-type person. He
Let's not forget that Tony was not a CEO-type person. He ran manufacturing. And I would guess that he was very good at doing that; but it doesn't necessarily translate into CEO skills (and it wouldn't prepare him for e.g. raising money).
And before Tony, there was Ken Van Ness (who wasn't any good at all). But we shouldn't be comparing NP vs. bad choices, we should be comparing him against professional, experienced, effective CEOs.
++++
My other comment regarding the long pro/con NP debate, is, yes, NP did pursue MONO. But to say that no one else would have is a stretch or at least a guess IMHO.
One could definitely make a cogent argument that we would be better off without having pursued MONO. Our COMBO results were more than good enough very early on. And our parallel MONO trial is what kept changing the goal posts by the FDA. We had more data (from MONO), and they kept wanting more and more. It is very likely that the FDA would have kept our COMBO trial the same as IZ. We would have been approved a long time ago and with only a fraction of the money required to be raised and diluted.
Moreover, IMO, MONO was a natural outcome from Lero. And IMO it would have come out as a use case irrespective of who was CEO. e.g COMBO patients would have started using it as MONO. All the CCR5 research data would have provided direction that it would/could work as MONO. Overlap with other indications would have directed the company to look closer into MONO.
We will never know for sure. But let's give NP full credit for MONO. Even in that case, the COMPANY would have been better off after that point in time hiring a seasoned CEO for no other reason than managing the business aspects.
But we are where we are. And as I have stated many times in the past, I invested and continue to invest in the company knowing that we have a suboptimal CEO that has not maximized the potential of the company. But the product is SOOOO good that the shareholders and the patients will benefit greatly nonetheless.
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...
Continue Reading
Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...
Continue Reading
Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...
Continue Reading
Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...
Continue Reading
A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...
Continue Reading
An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...
Continue Reading
They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...
Continue Reading
Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...
Continue Reading
Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...
Continue Reading
Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...
Continue Reading
Top 5 Most Recently Viewed Articles
Old Hickory Bourbon Unveils New Aged Whiskey Offerings Old Hickory Bourbon proudly announces the launch of its latest age-stated releases: the Hermitage Reserve 12-year-old Rye and the 15-year-old Barrel Proof Whiskey. These unique bourbons not only reflect the brand's rich heritage but also cater to both seasoned collectors and newcomers eager to explore the depth of...
Continue Reading
Goodix's Latest Move in the Display Tech Arena Ever thought about the tech behind your device's display? Well, buckle up, because Goodix just rolled out something that's going to make those screens snappier. Their GT9976 series of touch screen controllers aren't merely upgrades—it's like handing a Ferrari's steering to your smartphone or tablet. Especially if you're...
Continue Reading
Heineken Holding N.V.'s Share Buyback Program Explained Heineken Holding N.V. has recently provided significant updates regarding its ongoing share buyback program, an initiative designed to enhance shareholder value and reflect financial strength. This program, which is expected to reach up to €750 million, underscores Heineken’s commitment to returning capital to...
Continue Reading
Unmind Secures Significant Funding for Workplace Wellbeing With a fresh wave of investment led by TELUS Global Ventures, Unmind is poised to revolutionize workplace mental health. This funding enables Unmind to offer innovative mental health solutions that cater to employee needs while boosting organizational health. Transforming Access to Mental Health Solutions Unmind,...
Continue Reading
Bybit TradFi Enhances Trading Opportunities Bybit, a prominent name in the cryptocurrency exchange landscape, is excited to share new advancements for its Bybit TradFi platform. The platform is set to remove barriers for users looking to trade in traditional markets. By offering stock Contracts for Differences (CFDs) and indices without any trading fees, Bybit TradFi aims...
Continue Reading